ReviewClinical research in cardiology : official journal of the German Cardiac Society2015
Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.
Review in Clinical research in cardiology : official journal of the German Cardiac Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Trial
- Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Trial
- Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
- Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment.Frontiers in cardiovascular medicine · 2021Review
- Chrysophanol Protects Against Acute Heart Failure by Inhibiting JNK1/2 Pathway in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Effects of early diuretic response to carperitide in acute decompensated heart failure treatment: A single-center retrospective study.PloS one · 2018Article
- Predictors of Long-Term Mortality and Frequent Re-Hospitalization in Patients with Acute Decompensated Heart Failure and Kidney Dysfunction Treated with Renin-Angiotensin System Blockers.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- IMPROV-ED study: outcomes after discharge for an episode of acute-decompensated heart failure and comparison between patients discharged from the emergency department and hospital wards.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Article
- Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Comorbid renal tubular damage and hypoalbuminemia exacerbate cardiac prognosis in patients with chronic heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Predicting mortality in patients with acute heart failure: Role of risk scores.World journal of cardiology · 2015Review
- Single baseline serum creatinine measurements predict mortality in critically ill patients hospitalized for acute heart failure.ESC heart failure · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal dysfunction is a frequent finding in patients with acute heart failure (AHF) and an important prognostic factor for adverse outcomes. Worsening of renal function occurs in 30-50% of patients hospitalised for AHF, and is associated with increased mortality, prolonged hospital stay and increased risk of readmission. Likely mechanisms involved in the decrease in renal function include impaired haemodynamics and activation of neurohormonal factors, such as the renin-angiotensin-aldosterone system, the sympathetic nervous system and the arginine-vasopressin system. Additionally, many drugs currently used to treat AHF have a detrimental effect on renal function. Therefore, pharmacotherapy for AHF should carefully take into account any potential complications related to renal function. Serelaxin, currently in clinical development for the treatment of AHF is a recombinant form of human relaxin-2, identical in structure to the naturally occurring human relaxin-2 peptide hormone that mediates cardiac and renal adaptations during pregnancy. Data from both pre-clinical and clinical studies indicate a potentially beneficial effect of serelaxin on kidney function. In this review, we discuss the mechanisms and impact of impairment of renal function in AHF, and the potential benefits of new therapies, such as serelaxin, in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.